Chi-Chu Liu1,2, Li-Ping Chou2,3, Tsang-Shan Chen4, Chien-An Chen5,6, Yueh-Feng Tsai7. 1. Department of Anesthesia, Tainan Sinlau Hospital, Tainan, Taiwan. 2. Department of Health Care Administration, Chang Jung Christian University, Tainan, Taiwan. 3. Department of Cardiology, Tainan Sinlau Hospital, Tainan, Taiwan. 4. Department of Neurology, Tainan Sinlau Hospital, Tainan, Taiwan. 5. Department of Health Care Administration, Chang Jung Christian University, Tainan, Taiwan. chen.chouml@msa.hinet.net. 6. Department of Nephrology, Tainan Sinlau Hospital, No. 57, 1 Sec., Dongmen Rd, Tainan, Taiwan. chen.chouml@msa.hinet.net. 7. Department of Nephrology, Tainan Sinlau Hospital, No. 57, 1 Sec., Dongmen Rd, Tainan, Taiwan.
Abstract
BACKGROUND: Hemodialysis patients have a high incidence of anti-platelet factor 4/heparin antibody (PF4-H Ab) and are at a high risk of cardiovascular disease. This study determines the association between PF4-H Ab and cardiovascular events including coronary artery disease (CAD), ischemic stroke (IS), and native arteriovenous fistula thrombosis (AVFT), in a longitudinal 7-year follow-up. PATIENTS AND METHODS: 84 hemodialysis patients were enrolled. Data collection included chart reviews and assessments of laboratory records. PF4-H Ab was evaluated by ELISA and a titer ≥ 0.4 was defined to have PF4-H Ab. RESULTS: 30 patients were PF4-H Ab positive, 30 patients had CAD, 29 patients had IS, and 43 patients had AVFT. In Cox proportional hazard regression analysis, PF4-H Ab (HR 2.72, p = 0.01) was a significant risk factor for CAD. Age (HR 1.06, p = 0.003), PF4-H Ab (HR 4.53, p < 0.001), 7-year averaged serum phosphate levels (HR 0.53, p = 0.012), and 7-year averaged blood platelet count (HR 1.01, p = 0.029) were risk factors for IS. Age (HR 1.03, p = 0.047), PF4-H Ab (HR 3.57, p < 0.001), and 7-year averaged serum triglyceride levels (HR 1.01, p = 0.005) were risk factors for AVFT. In PF4-H Ab-positive groups, thrombocytopenia was not associated with CAD, IS, and AVFT by Fisher's test analysis. CONCLUSION: This study reveals that PF4-H Ab is a risk factor for developing CAD, IS, and AVFT among hemodialysis patients.
BACKGROUND: Hemodialysis patients have a high incidence of anti-platelet factor 4/heparin antibody (PF4-H Ab) and are at a high risk of cardiovascular disease. This study determines the association between PF4-H Ab and cardiovascular events including coronary artery disease (CAD), ischemic stroke (IS), and native arteriovenous fistula thrombosis (AVFT), in a longitudinal 7-year follow-up. PATIENTS AND METHODS: 84 hemodialysis patients were enrolled. Data collection included chart reviews and assessments of laboratory records. PF4-H Ab was evaluated by ELISA and a titer ≥ 0.4 was defined to have PF4-H Ab. RESULTS: 30 patients were PF4-H Ab positive, 30 patients had CAD, 29 patients had IS, and 43 patients had AVFT. In Cox proportional hazard regression analysis, PF4-H Ab (HR 2.72, p = 0.01) was a significant risk factor for CAD. Age (HR 1.06, p = 0.003), PF4-H Ab (HR 4.53, p < 0.001), 7-year averaged serum phosphate levels (HR 0.53, p = 0.012), and 7-year averaged blood platelet count (HR 1.01, p = 0.029) were risk factors for IS. Age (HR 1.03, p = 0.047), PF4-H Ab (HR 3.57, p < 0.001), and 7-year averaged serum triglyceride levels (HR 1.01, p = 0.005) were risk factors for AVFT. In PF4-H Ab-positive groups, thrombocytopenia was not associated with CAD, IS, and AVFT by Fisher's test analysis. CONCLUSION: This study reveals that PF4-H Ab is a risk factor for developing CAD, IS, and AVFT among hemodialysis patients.
Authors: Lourdes Pena de la Vega; Randal S Miller; Margaret M Benda; Diane E Grill; Matthew G Johnson; James T McCarthy; Robert D McBane Journal: Mayo Clin Proc Date: 2005-08 Impact factor: 7.616
Authors: J F Arthur; J Qiao; Y Shen; A K Davis; E Dunne; M C Berndt; E E Gardiner; R K Andrews Journal: J Thromb Haemost Date: 2012-06 Impact factor: 5.824
Authors: Marc Carrier; Greg A Knoll; Michael J Kovacs; Jane C Moore; Dean Fergusson; Marc A Rodger Journal: Thromb Res Date: 2006-11-13 Impact factor: 3.944
Authors: Lars M Asmis; Jodi B Segal; Laura C Plantinga; Nancy E Fink; Jonathan S Kerman; Thomas S Kickler; Josef Coresh; Lawrence B Gardner Journal: Thromb Haemost Date: 2008-09 Impact factor: 5.249
Authors: Susan K Morton; Alexander J Rodríguez; Dylan R Morris; Abhishta P Bhandari; Joseph V Moxon; Jonathan Golledge Journal: PLoS One Date: 2016-07-26 Impact factor: 3.240